Skip to content

Journal · Oncology · Updated 21 November 2026

Targeted Oncology

Read Targeted Oncology articles on DeepDyve. No university library needed.

Targeted Oncology has published since 2006 and covers targeted cancer treatment, from early drug trials and tumor biomarkers to precision medicine in pancreatic, colorectal and blood cancers. Springer Nature publishes it. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.

Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.

Personal plans aren’t for business use. Reading for work? See Enterprise.

Cover of Targeted Oncology
Journal cover

Targeted Oncology at a glance

Full title
Targeted Oncology
Abbreviation (NLM)
Target Oncol
Publisher
Springer Nature
Print ISSN
1776-2596
Online ISSN (eISSN)
1776-260X
First published
2006
Subjects
Neoplasms
Access model
Hybrid (69% free to read in 2026)

Ways to access Targeted Oncology

69% of the articles Targeted Oncology published from January 1 to November 19, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.

  1. Open access articles. 69% of Targeted Oncology articles published from January 1 to November 19, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
  2. The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
  3. Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
  4. NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
  5. A library. Your university, hospital or public library may subscribe to Targeted Oncology. Check its journal list and whether it offers remote access.
  6. DeepDyve. Read Targeted Oncology articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.

Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.

Impact factor and metrics

Targeted Oncology’s 2025 Journal Impact Factor is 5.1, and its 5-year Impact Factor is 5.0.

5.1

Journal Impact Factor (2025)

5.0

5-year Impact Factor (2025)

5 days

Median time to first decision

Source: journal metrics on the Targeted Oncology homepage (Springer Nature), checked November 21, 2026. Impact Factor from Clarivate Journal Citation Reports.

Recent Targeted Oncology research worth reading

Published January to April 2026. Summaries describe what the authors report.

  1. LitStreamKidney cancer · Immunotherapy

    Time-Dependent Comparative Effectiveness of First-Line Treatment for Metastatic Clear Cell Renal Cell Carcinoma: A Restricted Mean Survival Time-Based Network Meta-analysis

    In a network meta-analysis of five phase III trials (4206 patients) in metastatic clear cell renal cell carcinoma, Fukushima and colleagues report that nivolumab plus cabozantinib ranked highest for overall survival at 12 to 48 months, and ipilimumab plus nivolumab beyond 48 months.

    Fukushima et al. · Targeted Oncology, published online January 23, 2026 · DOI 10.1007/s11523-025-01194-w

  2. Open accessSolid tumors · Early-phase trials

    First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies

    In a first-in-human trial of 60 patients with advanced solid tumors, the authors report that the dual PAK4 and NAMPT inhibitor KPT-9274 showed no clinical activity alone or with niacin or nivolumab, and enrollment was stopped early.

    Razak et al. · Targeted Oncology, published online March 13, 2026 · DOI 10.1007/s11523-026-01206-3

  3. Open accessColorectal cancer · Tumor microenvironment

    Therapeutic Strategies Targeting the Tumor–Stromal Microenvironment in Colorectal Cancer: A Narrative Review

    The authors review tumor stroma as a biomarker and treatment target in colorectal cancer, noting that drugs aimed at the stroma alone have largely failed to improve survival, while combinations with standard treatment look more promising.

    Heilijgers et al. · Targeted Oncology, published online April 27, 2026 · DOI 10.1007/s11523-026-01220-5

  4. LitStreamMultiple myeloma · Immunotherapy

    Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What’s the Current Status?

    The authors review the pivotal trials, real-world evidence and resistance mechanisms for antibody-drug conjugates, bispecific T-cell engagers and CAR T-cell therapies targeting BCMA and GPRC5D in multiple myeloma, several of which are now approved in Europe and the US.

    Segers et al. · Targeted Oncology, published online January 21, 2026 · DOI 10.1007/s11523-025-01189-7

  5. LitStreamImmunotherapy · Drug safety

    Infusion-Related Reactions from Immune Checkpoint Inhibitors in Solid Tumors: A Proportional and Network Meta-Analysis

    In a meta-analysis of 61 phase 3 trials with 40,872 patients, Fujiwara and colleagues report pooled infusion-related reaction rates of 2.31% for PD-1 inhibitors and 8.27% for PD-L1 inhibitors, with avelumab carrying the highest risk, followed by atezolizumab and dual checkpoint inhibitors.

    Fujiwara et al. · Targeted Oncology, published online April 17, 2026 · DOI 10.1007/s11523-026-01212-5

See every Targeted Oncology article on DeepDyve

Questions about Targeted Oncology

How can I read Targeted Oncology articles without a subscription?

69% of Targeted Oncology articles published from January 1 to November 19, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Targeted Oncology articles online for $59 a month or $499 a year after a free first month.

What is the abbreviation for Targeted Oncology?

Targeted Oncology’s NLM (PubMed) abbreviation is Target Oncol.

What is the ISSN of Targeted Oncology?

The print ISSN is 1776-2596 and the online ISSN is 1776-260X.

What is the impact factor of Targeted Oncology?

Targeted Oncology’s Journal Impact Factor is 5.1 (2025), and its 5-year Impact Factor is 5.0, according to Springer Nature’s published metrics.

Is Targeted Oncology open access?

Targeted Oncology is a hybrid journal: authors can choose to publish open access or under the subscription model. From January 1 to November 19, 2026, 52 of 75 Targeted Oncology articles (69%) carry a Creative Commons license, per Crossref.

Targeted Oncology articles on DeepDyve are licensed from Springer Nature. Journal facts as of 21 November 2026.

Start reading Targeted Oncology today

One month free, then less than $2 a day. Targeted Oncology, plus millions of articles from thousands of journals.

Start free month

Like this: